Gary McLean is an Honorary Research Fellow in the Airway Disease Infection Section of the National Heart and Lung Institute.
His prior research on blood cell development, immune responses to human viral pathogens and molecular studies of antibody generation were performed in North America.
Currently his research investigates immune responses to rhinovirus infections and the role of microvesicles in the spread of respiratory viral infections - the aim of his research is to generate novel therapeutic interventions or a protective vaccine to rhinovirus.
et al., 2020, IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus, Immunology, ISSN:0019-2805
et al., 2020, An investigation of rhinovirus infection on cellular uptake of poly (glycerol-adipate) nanoparticles, International Journal of Pharmaceutics, Vol:589, ISSN:0378-5173
et al., 2020, A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection, European Journal of Pharmaceutical Sciences, Vol:153, ISSN:0928-0987
et al., 2020, Identification of similar epitopes between severe acute respiratory syndrome coronavirus-2 and Bacillus Calmette-Guérin: potential for cross-reactive adaptive immunity., Clin Transl Immunology, Vol:9, ISSN:2050-0068
McLean GR, 2019, Vaccine strategies to induce broadly protective immunity to rhinoviruses, Human Vaccines & Immunotherapeutics, Vol:16, ISSN:2164-5515, Pages:684-686